Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high‐resolution PET study

The dopamine (DA) system is known to be involved in the reward and dependence mechanisms of addiction. However, modifications in dopaminergic neurotransmission associated with long‐term tobacco and cannabis use have been poorly documented in vivo. In order to assess striatal and extrastriatal dopamine transporter (DAT) availability in tobacco and cannabis addiction, three groups of male age‐matched subjects were compared: 11 healthy non‐smoker subjects, 14 tobacco‐dependent smokers (17.6 ± 5.3 cigarettes/day for 12.1 ± 8.5 years) and 13 cannabis and tobacco smokers (CTS) (4.8 ± 5.3 cannabis joints/day for 8.7 ± 3.9 years). DAT availability was examined in positron emission tomography (HRRT) with a high resolution research tomograph after injection of [11C]PE2I, a selective DAT radioligand. Region of interest and voxel‐by‐voxel approaches using a simplified reference tissue model were performed for the between‐group comparison of DAT availability. Measurements in the dorsal striatum from both analyses were concordant and showed a mean 20% lower DAT availability in drug users compared with controls. Whole‐brain analysis also revealed lower DAT availability in the ventral striatum, the midbrain, the middle cingulate and the thalamus (ranging from −15 to −30%). The DAT availability was slightly lower in all regions in CTS than in subjects who smoke tobacco only, but the difference does not reach a significant level. These results support the existence of a decrease in DAT availability associated with tobacco and cannabis addictions involving all dopaminergic brain circuits. These findings are consistent with the idea of a global decrease in cerebral DA activity in dependent subjects.

[1]  Matthijs G. Bossong,et al.  Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum , 2008, NeuroImage.

[2]  Zhuang-Wei Xiao,et al.  Changes of dopamine transporter function in striatum during acute morphine addiction and its abstinence in rhesus monkey. , 2006, Chinese medical journal.

[3]  Iwao Kanno,et al.  Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. , 2008, The international journal of neuropsychopharmacology.

[4]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[5]  Pirkko Räsänen,et al.  Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography☆ , 2003, NeuroImage.

[6]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[7]  Paul J. Laurienti,et al.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets , 2003, NeuroImage.

[8]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[9]  T. Kirkham,et al.  Endocannabinoids in the regulation of appetite and body weight , 2005, Behavioural pharmacology.

[10]  Christer Halldin,et al.  Measurement of Striatal and Extrastriatal Dopamine Transporter Binding with High-Resolution PET and [11C]PE2I: Quantitative Modeling and Test—Retest Reproducibility , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  Jeffrey H. Meyer,et al.  Smoking-induced ventral striatum dopamine release. , 2004, The American journal of psychiatry.

[12]  Rita Z. Goldstein,et al.  Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. , 2002, The American journal of psychiatry.

[13]  D. Guilloteau,et al.  Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I , 1999, NeuroImage.

[14]  R. Metzger,et al.  Rapid and reversible effects of methamphetamine on dopamine transporters. , 1997, The Journal of pharmacology and experimental therapeutics.

[15]  Alain Dagher,et al.  The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride , 2004, Synapse.

[16]  J. McEvoy,et al.  Striatal dopamine D2/D3 receptor availability in male smokers , 2006, Psychiatry Research: Neuroimaging.

[17]  F. Yasuno,et al.  Role of Ventral Striatal Dopamine D1 Receptor in Cigarette Craving , 2007, Biological Psychiatry.

[18]  Gwenn S. Smith,et al.  Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography , 2008, Psychopharmacology.

[19]  C. Hart,et al.  Neuropsychological deficits in long-term frequent cannabis users , 2006, Neurology.

[20]  N. Volkow,et al.  Imaging dopamine's role in drug abuse and addiction , 2009, Neuropharmacology.

[21]  Gerome Breen,et al.  Can recreational doses of THC produce significant dopamine release in the human striatum? , 2009, NeuroImage.

[22]  J. Swanson,et al.  Dopamine in drug abuse and addiction: results from imaging studies and treatment implications , 2004, Molecular Psychiatry.

[23]  J. Heikkilä,et al.  Dopamine transporters increase in human brain after alcohol withdrawal , 1999, Molecular Psychiatry.

[24]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Hans-Georg Buchholz,et al.  Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. , 2008, The American journal of psychiatry.

[26]  Ralph Myers,et al.  Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.

[27]  Caryn Lerman,et al.  Dopamine Transporter Binding in Smokers and Nonsmokers , 2007, Clinical nuclear medicine.

[28]  Nora D. Volkow,et al.  The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies , 2004, Neuropharmacology.

[29]  Po See Chen,et al.  Decreased dopamine transporter availability in male smokers — A dual isotope SPECT study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[30]  Joseph A Maldjian,et al.  Precentral gyrus discrepancy in electronic versions of the Talairach atlas , 2004, NeuroImage.

[31]  Jennifer M. Mitchell,et al.  Behavioural and biochemical evidence for interactions between Δ9‐tetrahydrocannabinol and nicotine , 2002, British journal of pharmacology.

[32]  Edythe D London,et al.  Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. , 2006, Archives of general psychiatry.

[33]  Claude Comtat,et al.  Assessment of 11C-PE2I Binding to the Neuronal Dopamine Transporter in Humans with the High-Spatial-Resolution PET Scanner HRRT , 2007, Journal of Nuclear Medicine.

[34]  R N Gunn,et al.  Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers , 2001, Synapse.

[35]  E. Perry,et al.  Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use , 1998, Neuroscience.

[36]  Jean-Luc Anton,et al.  Region of interest analysis using an SPM toolbox , 2010 .

[37]  Alice Egerton,et al.  The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study , 2007, Synapse.

[38]  N. Rathod Society for the Study of Addiction , 1977 .

[39]  Jean-Francois Mangin,et al.  A structural browser for human brain mapping , 2000, NeuroImage.

[40]  L. Kozlowski,et al.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.

[41]  R. Murray,et al.  Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study , 2011, Journal of psychopharmacology.

[42]  M Fujita,et al.  Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers , 2001, Synapse.

[43]  Robert A Koeppe,et al.  Smoking Modulation of μ-Opioid and Dopamine D2 Receptor-Mediated Neurotransmission in Humans , 2007, Neuropsychopharmacology.

[44]  A. Galli,et al.  Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. , 2003, European journal of pharmacology.

[45]  J. Seibyl,et al.  Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[46]  G. Di Chiara,et al.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. , 1997, Science.

[47]  J. Monterosso,et al.  Ventral Striatal Dopamine Release in Response to Smoking a Regular vs a Denicotinized Cigarette , 2009, Neuropsychopharmacology.

[48]  Ronald Boellaard,et al.  Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner , 2007, Physics in medicine and biology.

[49]  M. Picciotto Nicotine as a modulator of behavior: beyond the inverted U. , 2003, Trends in pharmacological sciences.

[50]  R. Wightman,et al.  Cannabinoids Enhance Subsecond Dopamine Release in the Nucleus Accumbens of Awake Rats , 2004, The Journal of Neuroscience.

[51]  E. Gardner Endocannabinoid signaling system and brain reward: Emphasis on dopamine , 2005, Pharmacology Biochemistry and Behavior.